Abstract:Pancreatic ductal adenocarcinoma is a highly lethal malignancy, which has now become the seventh most common cause of cancer death in the world, with the highest mortality rates in Europe and North America. In the past 30 years, there has been some progress in 5-year survival (rates increasing from 2.5 to 10%), but this is still extremely poor compared to all other common cancer types. Targeted therapies for advanced pancreatic cancer based on actionable mutations have been disappointing, with only 3–5% showing even a short clinical benefit. There is, however, a molecular diversity beyond mutations in genes responsible for producing classical canonical signaling pathways. Pancreatic cancer is almost unique in promoting an excess production of other components of the stroma, resulting in a complex tumor microenvironment that contributes to tumor development, progression, and response to treatment. Various transcriptional subtypes have also been described. Most notably, there is a strong alignment between the Classical/Pancreatic progenitor and Quasi-mesenchymal/Basal-like/Squamous subtype signatures of Moffit, Collinson, Bailey, Puleo, and Chan-Seng-Yue, which have potential clinical impact. Sequencing of epithelial cell populations enriched by laser capture microscopy combined with single-cell RNA sequencing has revealed the potential genomic evolution of pancreatic cancer as being a consequence of a gene expression continuum from mixed Basal-like and Classical cell populations within the same tumor, linked to allelic imbalances in mutant KRAS, with metastatic tumors being more copy number-unstable compared to primary tumors. The Basal-like subtype appears more chemoresistant with reduced survival compared to the Classical subtype. Chemotherapy and/or chemoradiation will also enrich the Basal-like subtype. Squamous/Basal-like programs facilitate immune infiltration compared with the Classical-like programs. The immune infiltrates associated with Basal and Classical type cells are distinct, potentially opening the door to differential strategies. Single-cell and spatial transcriptomics will now allow single cell profiling of tumor and resident immune cell populations that may further advance subtyping. Multiple clinical trials have been launched based on transcriptomic response signatures and molecular subtyping including COMPASS, Precision Promise, ESPAC6/7, PREDICT-PACA, and PASS1. We review several approaches to explore the clinical relevance of molecular profiling to provide optimal bench-to-beside translation with clinical impact.

Retrospective analysis of pathological types and imaging features in pancreatic cancer: A comprehensive study

Comparative study of clinical and imaging features of pancreatic adenosquamous carcinoma and pancreatic ductal adenocarcinoma

Accurate imaging diagnosis and evaluation of pancreatic cancer

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

110 Patients with Adenosquamous Carcinomas of the Pancreas (PASC): Imaging Differentiation of Small (≤ 3 Cm) Versus Large (> 3 Cm) Tumors

Diagnostic value of imaging examinations in pancreatic cystic neoplasm

Pathomic and bioinformatics analysis of clinical-pathological and genomic factors for pancreatic cancer prognosis

Biological Characteristics of Pancreatic Ductal Adenocarcinoma: Initiation to Malignancy, Intracellular to Extracellular.

Exploring the biological basis of CT imaging features in pancreatic neuroendocrine tumors: a two-center study

Characteristics and Outcomes of Pancreatic Cancer by Histological Subtypes.

Pancreatic neuroendocrine tumors：comparison of the atypical imaging findings and the pathology

Can Imaging Using Radiomics and Fat Fraction Analysis Detect Early Tissue Changes on Historical CT Scans in the Regions of the Pancreas Gland That Subsequently Develop Adenocarcinoma?

Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review

Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma

Pancreatic Adenocarcinoma Associated to Intraductal Papillary Mucinous Neoplasia: Histopathological Particularities and Clinical Implications

The Clinical Significance of Pancreatic Steatosis in Pancreatic Cancer: A Hospital-Based Study

Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages

Clinicopathological Analysis of Cystic Pancreatic Carcinoma in 37 Cases

Clinical Impact of Molecular Subtyping of Pancreatic Cancer

The Prognostic Value of Multidetector CT Features in Predicting Overall Survival Outcomes in Patients with Pancreatic Neuroendocrine Tumors.

Comparative Genomic Analysis of Head and Body/tail of Pancreatic Ductal Adenocarcinoma at Early and Late Stages.